<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="129606">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02127476</url>
  </required_header>
  <id_info>
    <org_study_id>6640-001</org_study_id>
    <secondary_id>2013-002873-23</secondary_id>
    <nct_id>NCT02127476</nct_id>
  </id_info>
  <brief_title>A Study of Single and Multiple Doses of KHK6640 in Subjects With Prodromal or Mild to Moderate Alzheimer's Disease</brief_title>
  <official_title>A Phase 1 Double-blind, Placebo-controlled, Single- and Multiple-ascending-dose Study of KHK6640 in Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyowa Hakko Kirin Pharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kyowa Hakko Kirin Pharma, Inc.</source>
  <oversight_info>
    <authority>Sweden: Medical Products Agency</authority>
    <authority>Germany: Paul-Ehrlich-Institut</authority>
    <authority>Finland: Finnish Medicines Agency</authority>
    <authority>Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)</authority>
    <authority>Belgium: Federal Agency for Medicines and Health Products, FAMHP</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of
      KHK6640, given as a single dose and as multiple doses in patients with Prodromal Alzheimer's
      Disease (AD) or Mild to Moderate AD.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Anticipated">February 2017</completion_date>
  <primary_completion_date type="Anticipated">November 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>Up to 7 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Safety assessment variables will include all adverse events (AEs) including serious and non-serious AEs, laboratory parameters (hematology, chemistry, and urinalysis), vital signs, 12-lead electrocardiograms, physical and neurological examinations, and brain MRI</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">62</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>KHK6640</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>KHK6640</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KHK6640</intervention_name>
    <description>Single ascending dose and multiple ascending doses administration</description>
    <arm_group_label>KHK6640</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Matching Placebo</intervention_name>
    <description>Single ascending dose and multiple ascending doses administration</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with prodromal AD or mild to moderate AD

          -  Clinical Dementia Rating (CDR) score of 0.5, 1.0, or 2.0

          -  Have a cognitive impairment

          -  Low Aβ and high Tau in Cerebrospinal fluid (CSF)

          -  Mini Mental State Examination (MMSE) score &gt; 16 at Screening

        Exclusion Criteria:

          -  Previous active treatment with an AD immunotherapy in an investigational study

          -  Use of another investigational drug within 30 days of screening

          -  History or presence of clinically significant seizures, brain trauma, transient
             ischemic attack, and/or cerebrovascular disease

          -  Presence of a neurological condition that could be contributing to cognitive
             impairment above and beyond that caused by the subject's AD

          -  Evidence of infection, tumor, or other clinically significant lesions that could
             indicate a dementia diagnosis other than AD
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Project Leader</last_name>
    <phone>+1 609-919-1100</phone>
    <email>clinical.info@kyowa-kirin-pharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Turku</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <zip>14050</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Mannheim</city>
        <zip>D-68159</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Zwolle</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Malmö</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mölndal</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Finland</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 28, 2014</lastchanged_date>
  <firstreceived_date>April 24, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
